Is co‑administration of azithromycin and colchicine safe, and should the colchicine dose be reduced?

Co-Administration of Azithromycin and Colchicine is Safe Without Dose Adjustment

Azithromycin does not require colchicine dose reduction and can be safely co-administered at standard doses. This is a critical distinction from other macrolide antibiotics like clarithromycin and erythromycin, which are contraindicated or require significant dose adjustments.

Key Evidence from Drug Labeling and Pharmacokinetic Studies

The FDA-approved colchicine labeling explicitly addresses this interaction. Unlike clarithromycin (a strong CYP3A4 inhibitor that increases colchicine levels by 277-282% and has caused fatal toxicity), azithromycin showed no clinically significant pharmacokinetic interaction with colchicine 1.

A dedicated pharmacokinetic study demonstrated that azithromycin, when co-administered with colchicine, did not produce the >125% increase in maximum concentration or area under the curve that was observed with other CYP3A4/P-glycoprotein inhibitors 2. The study concluded that no dose adjustment is needed when colchicine is used in combination with azithromycin 2.

Why Azithromycin is Different from Other Macrolides

While clarithromycin and erythromycin are potent CYP3A4 inhibitors that dramatically increase colchicine plasma levels, azithromycin has minimal effect on this metabolic pathway. This pharmacologic difference is clinically crucial:

• Clarithromycin: Strong CYP3A4 inhibitor - contraindicated with colchicine or requires 50-75% dose reduction 3, 4
• Erythromycin: Moderate CYP3A4 inhibitor - requires dose reduction 1
• Azithromycin: Minimal CYP3A4 inhibition - no dose adjustment needed 2

Clinical Application

For patients on colchicine therapy (whether for gout prophylaxis, acute gout treatment, or familial Mediterranean fever):

Continue colchicine at the current dose when prescribing azithromycin:

• Gout prophylaxis: 0.6 mg once or twice daily (unchanged)
• Acute gout treatment: 1.2 mg followed by 0.6 mg one hour later (unchanged)
• FMF: 1.2-2.4 mg daily (unchanged)

Important Caveats

While azithromycin itself doesn't require colchicine dose adjustment, remain vigilant for:

1. Renal impairment: Colchicine toxicity risk increases dramatically with decreased kidney function regardless of drug interactions 5

2. Concomitant use of other CYP3A4/P-gp inhibitors: If the patient is taking statins, calcium channel blockers, or other interacting medications, those interactions still apply 5, 6

3. Signs of colchicine toxicity: Diarrhea, nausea, vomiting, abdominal pain, and in severe cases, bone marrow suppression and multiorgan failure 5, 7

This represents a practical advantage of azithromycin over other macrolides when treating infections in patients requiring colchicine therapy, as it avoids the complexity and risk of dose adjustments.